PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jul 30, 2026
$63.46
· of 52w range
· above low
· to high
$61.2352w low
$90.8752w high
Market Cap (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Revenue (TTM)
$1.01B
your badges
52W Range
$61–$91
Analyst Rating
BUY
Price Target
$102
P/E
-117.5
ROE
20.6%
Net Profit Margin
-3.8%
Your badge strip is empty — pin a metric anywhere on this page.
PTCT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$63.46
Market Cap (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Revenue (TTM)
$1.01B
ROE (TTM)
20.6%
Debt/Equity (MRQ)
-3.6
52W Range
$61–$91
PTCT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About PTC Therapeutics, Inc. - Common Stock Company overview from Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees991
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
Free Cash Flow$702M2016-12-31 → 2025-12-31
Net margin-3.8%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | PTCT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -117.55Y avg ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.25Y avg ≈3.8 | ≈3.8 | 55.0 | Undervalued | |
| P/B (MRQ) | -32.05Y avg ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.25Y avg ≈-5.5 | ≈-5.5 | · | · | |
| Price / FCF (TTM) | -133.25Y avg ≈-10.8 | ≈-10.8 | · | · | |
| Price / Cash Flow (TTM) | -173.45Y avg ≈-12.1 | ≈-12.1 | · | · | |
| EV / Revenue (TTM) | 3.65Y avg ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.95Y avg ≈-8.4 | ≈-8.4 | · | · | |
| Price / Tangible Book (MRQ) | -9.3 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | PTCT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 12.5%5Y avg ≈-25.9% | ≈-25.9% | -24.1% | Top tier | |
| EBITDA Margin (TTM) | 17.9%5Y avg ≈-13.8% | ≈-13.8% | -24.1% | Top tier | |
| Pretax Margin (TTM) | -6.6%5Y avg ≈-43.8% | ≈-43.8% | -28.9% | Top tier | |
| Net Profit Margin (TTM) | -3.8%5Y avg ≈-42.4% | ≈-42.4% | -38.1% | Top tier | |
| ROA (TTM) | -1.3%5Y avg ≈-12.6% | ≈-12.6% | -27.7% | Top tier | |
| ROE (TTM) | 20.6%5Y avg ≈-299.7% | ≈-299.7% | -40.8% | Weak | |
| ROIC | 1044.7%5Y avg ≈267.1% | ≈267.1% | -37.7% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | PTCT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | -3.65Y avg ≈74.5 | ≈74.5 | · | · | |
| Current Ratio (MRQ) | 3.45Y avg ≈2.1 | ≈2.1 | 8.3 | Low liquidity | |
| Quick Ratio (MRQ) | 3.25Y avg ≈2.0 | ≈2.0 | 3.2 | In line | |
| Long-Term Debt / Equity (MRQ) | -3.25Y avg ≈65.1 | ≈65.1 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | PTCT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 114.5%5Y avg ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y | 35.3%5Y avg ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | PTCT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.85Y avg ≈0.5 | ≈0.5 | 0.4 | Top tier | |
| Receivables Turnover | 10.25Y avg ≈6.8 | ≈6.8 | 9.7 | In line | |
| Revenue / Employee | ≈$1.7M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
105.2%
Next Report
Nov 02, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $0.92 | $0.43 | 116.4% |
| March 31, 2026 | $-0.03 | $-0.48 | 93.7% | |
| Dec. 31, 2025 | $-1.67 | $0.04 | -4460.3% | |
| Sept. 30, 2025 | $0.20 | $-1.40 | 114.3% | |
| June 30, 2025 | $-0.83 | $-1.08 | 23.3% | |
| March 31, 2025 | $10.04 | $-0.22 | 4743.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M |
| Operating Margin % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M |
| Diluted EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M |
Institutional owners (13F) 403 filers · $8.6B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
403
Value held
$8.6B
New positions
76
Exited positions
43
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 76 (+7 vs prior Q) | 43 (-7 vs prior Q) | 140 (+3 vs prior Q) | 114 (+10 vs prior Q) | -1.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $1,139,088,671 | 13,964,554 | 13.21% | Shares |
| VANGUARD GROUP INC | $668,691,300 | 8,803,203 | 7.75% | Shares |
| RTW INVESTMENTS, LP | $631,875,072 | 7,746,415 | 7.33% | Shares |
| JANUS HENDERSON GROUP PLC | $489,997,100 | 7,193,433 | 5.68% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401,986,014 | 4,928,111 | 4.66% | Shares |
| STATE STREET CORP | $375,136,515 | 4,598,952 | 4.35% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $336,743,228 | 4,128,273 | 3.90% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $305,000,589 | 3,739,127 | 3.54% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $180,089,116 | 2,207,376 | 2.09% | Shares |
| TORONTO DOMINION BANK | $176,668,031 | 2,165,846 | 2.05% | Shares |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159,563,645 | 1,956,156 | 1.85% | Shares |
| Hood River Capital Management LLC | $141,818,662 | 1,738,613 | 1.64% | Shares |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140,519,660 | 1,722,688 | 1.63% | Shares |
| D. E. Shaw & Co., Inc. | $126,345,323 | 1,548,919 | 1.47% | Shares |
| TANG CAPITAL MANAGEMENT LLC | $122,355,000 | 1,500,000 | 1.42% | Shares |
| BANK OF AMERICA CORP /DE/ | $118,462,234 | 1,452,277 | 1.37% | Shares |
| Driehaus Capital Management LLC | $117,469,528 | 1,440,107 | 1.36% | Shares |
| FMR LLC | $114,056,206 | 1,398,261 | 1.32% | Shares |
| Jefferies Financial Group Inc. | $110,693,916 | 1,357,042 | 1.28% | Shares |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94,361,749 | 1,156,819 | 1.09% | Shares |
| Pictet Asset Management Holding SA | $93,629,635 | 1,147,844 | 1.09% | Shares |
| MORGAN STANLEY | $90,026,886 | 1,103,675 | 1.04% | Shares |
| ARMISTICE CAPITAL, LLC | $87,393,690 | 1,071,395 | 1.01% | Shares |
| Blue Sparrow, LLC /DE | $85,705,599 | 1,050,700 | 0.99% | Shares |
| FRANKLIN RESOURCES INC | $83,799,082 | 1,027,327 | 0.97% | Shares |
| Invesco Ltd. | $76,804,761 | 941,581 | 0.89% | Shares |
| Palo Alto Investors LP | $74,950,268 | 918,846 | 0.87% | Shares |
| NORTHERN TRUST CORP | $71,783,966 | 880,029 | 0.83% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64,449,436 | 790,112 | 0.75% | Shares |
| CITADEL ADVISORS LLC | $60,999,840 | 747,822 | 0.71% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $59,015,895 | 723,500 | 0.68% | Shares |
| Boston Partners | $58,606,553 | 718,574 | 0.68% | Shares |
| JUPITER ASSET MANAGEMENT LTD | $57,706,697 | 707,450 | 0.67% | Shares |
| MARSHALL WACE, LLP | $57,489,476 | 704,787 | 0.67% | Shares |
| JPMORGAN CHASE & CO | $56,073,502 | 684,042 | 0.65% | Shares |
| ARMISTICE CAPITAL, LLC | $53,836,200 | 660,000 | 0.62% | Call option |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53,377,940 | 654,382 | 0.62% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $52,017,434 | 637,704 | 0.60% | Shares |
| GOLDMAN SACHS GROUP INC | $50,430,408 | 618,247 | 0.58% | Shares |
| LOOMIS SAYLES & CO L P | $48,156,807 | 590,374 | 0.56% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $47,953,943 | 587,887 | 0.56% | Shares |
| Nuveen, LLC | $47,622,931 | 583,829 | 0.55% | Shares |
| Bank of New York Mellon Corp | $45,145,865 | 553,462 | 0.52% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $44,181,166 | 541,635 | 0.51% | Shares |
| VOYA INVESTMENT MANAGEMENT LLC | $43,992,251 | 539,319 | 0.51% | Shares |
| Ensign Peak Advisors, Inc | $41,442,128 | 508,056 | 0.48% | Shares |
| AMERICAN CENTURY COMPANIES INC | $40,866,277 | 500,995 | 0.47% | Shares |
| FEDERATED HERMES, INC. | $39,432,896 | 483,424 | 0.46% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36,050,432 | 441,957 | 0.42% | Shares |
| Parkman Healthcare Partners LLC | $35,539,315 | 435,691 | 0.41% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 filings | Jan. 30, 2015 | · | Initial filing | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 filings | Nov. 12, 2014 | · | Initial filing | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | July 5, 2013 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 37 insiders · 15 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Aug. 4, 2026 S | 383,868 | 0 | 13 | $-4,219,888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | Jan. 31, 2023 S | 54,903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | July 14, 2026 S | 83,986 | 0 | 3 | $-652,864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | March 27, 2023 S | 38,925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | May 9, 2017 M | 37,850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | Jan. 15, 2015 M | 39,247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | Feb. 10, 2020 M | 6,744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | Aug. 17, 2026 M | 105,272 | 0 | 63 | $-5,955,553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | July 9, 2026 M | 60,299 | 0 | 62 | $-25,989,291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | June 17, 2026 M | 70,199 | 0 | 5 | $-1,941,426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | June 10, 2026 S | 73,411 | 0 | 28 | $-7,477,160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | April 2, 2026 S | 79,115 | 0 | 6 | $-1,081,515 |
| Mark Rothera | Chief Commercial Officer | May 24, 2017 M | 33,739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | Jan. 3, 2017 A | 6,000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | Jan. 4, 2016 A | 3,239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Director | Sept. 30, 2026 M | 22,500 | 0 | 2 | $-1,698,120 |
| Michael Schmertzler | Director | Sept. 17, 2026 S | 1,296,594 | 0 | 16 | $-6,313,453 |
| Hege Elisabeth Sollie-Zetlmayer | Director | July 28, 2026 A | 52,526 | 0 | 0 | $0 |
| Mary L. Smith | Director | July 9, 2026 M | 21,813 | 0 | 2 | $-1,425,060 |
| Jessica Caroline Chutter | Director | March 24, 2026 A | 7,333 | 0 | 0 | $0 |
| Stephanie Okey | Director | March 10, 2026 M | 8,000 | 0 | 3 | $-1,463,076 |
| Emma Reeve | Director | Jan. 5, 2026 M | 10,666 | 0 | 15 | $-4,229,530 |
| Alethia Young | Director | Jan. 2, 2026 A | 21,067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Director | Jan. 2, 2026 A | 21,451 | 0 | 11 | $-2,912,018 |
| Jerome B Zeldis | Director | Jan. 2, 2026 A | 22,500 | 0 | 0 | $0 |
| William F. Bell Jr. | Director | Feb. 15, 2024 A | 10,333 | 0 | 0 | $0 |
| Dawn Svoronos | Director | June 9, 2022 S | 29,017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Director | Jan. 3, 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Director | Jan. 3, 2017 A | 2,333,333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Director | Jan. 3, 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Director | June 8, 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Director | March 16, 2015 S | 2,242 | 0 | 0 | $0 |
| Axel Bolte | Director | June 25, 2013 P | 20,000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | 10% owner | Dec. 17, 2013 S | 2,441,504 | 0 | 0 | $0 |
| David P Southwell | · | Jan. 2, 2026 A | 20,850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | April 28, 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | June 25, 2013 C | 2,256,882 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 68 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 3.74% | 4,145 SH | Sept. 11, 2026 | Daily |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2.93% | 79,357 SH | Oct. 2, 2026 | Daily |
| PBE · Invesco Exchange-Traded Fund Trust | 2.47% | 159,717 SH | Oct. 2, 2026 | Daily |
| MEDI · Harbor ETF Trust | 1.31% | 7,913 NS | July 31, 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1.25% | 18,062 NS | July 31, 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1.23% | 22,852 SH | Oct. 2, 2026 | Daily |
| JSML · Janus Detroit Street Trust | 1.03% | 54,825 NS | July 31, 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0.94% | 145,033 NS | July 31, 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.74% | 98,733 SH | Aug. 19, 2026 | Daily |
| VAMO · Cambria ETF Trust | 0.72% | 11,494 NS | July 31, 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0.71% | 5,120 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.63% | 46,006 NS | July 31, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.49% | 658 NS | July 31, 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.42% | 3,031 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.40% | 613,266 SH | Sept. 11, 2026 | Daily |
| BRNY · EA Series Trust | 0.39% | 33,006 NS | July 31, 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.37% | 290,018 SH | Aug. 19, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.36% | 5,891 SH | Oct. 2, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.34% | 75,795 SH | Aug. 19, 2026 | Daily |
| ESSC · Strategy Shares | 0.34% | 1,785 NS | July 31, 2026 | N-PORT |
| IWO · iShares Trust | 0.31% | 664,357 SH | Sept. 11, 2026 | Daily |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.27% | 22,505 NS | July 31, 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.25% | 25,676 NS | July 31, 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0.24% | 3,125 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.20% | 477,030 SH | Aug. 19, 2026 | Daily |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.19% | 19,797 NS | July 31, 2026 | N-PORT |
| SMDX · Tidal Trust III | 0.19% | 3,667 NS | July 31, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.19% | 1,099,640 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.18% | 2,118,779 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.18% | 39,691 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.18% | 629 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.16% | 23,005 SH | Sept. 11, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.16% | 65,468 SH | Oct. 2, 2026 | Daily |
| LRGF · iShares Trust | 0.16% | 84,774 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.14% | 35,428 SH | Aug. 19, 2026 | Daily |
| FSMD · FIDELITY COVINGTON TRUST | 0.14% | 51,459 NS | July 31, 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0.14% | 18,636 NS | July 31, 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.13% | 5,320 SH | Oct. 2, 2026 | Daily |
| FBUF · Fidelity Greenwood Street Trust | 0.12% | 413 NS | July 31, 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0.11% | 3,600 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.10% | 224,327 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.08% | 952,071 SH | Aug. 19, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.08% | 1,902,509 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.08% | 211,842 SH | Aug. 19, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.08% | 6,756 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.07% | 33,487 NS | July 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.06% | 12,627 NS | July 31, 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0.06% | 18,932 SH | Oct. 2, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.06% | 10,557 SH | Aug. 19, 2026 | Daily |
| ESML · iShares Trust | 0.06% | 22,893 SH | Sept. 11, 2026 | Daily |
| WSML · iShares Trust | 0.04% | 4,360 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.01% | 4,108 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.01% | 2,636,335 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 66,405 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 6,819 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.01% | 18,275 SH | Aug. 19, 2026 | Daily |
| ITOT · iShares Trust | 0.01% | 109,219 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.01% | 22,686 SH | Sept. 10, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.01% | 43,296 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 1,090 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 284 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 249 NS | July 31, 2026 | N-PORT |
| IJR · iShares Trust | · | 5,061,986 SH | Sept. 10, 2026 | Daily |
| IJT · iShares Trust | · | 784,746 SH | Sept. 9, 2026 | Daily |
| IWN · iShares Trust | · | 114,658 SH | Sept. 11, 2026 | Daily |
| XJR · iShares Trust | · | 11,464 SH | Aug. 31, 2026 | Daily |
| ISCB · iShares Trust | · | 3,281 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 64,380 SH | Sept. 11, 2026 | Daily |
PTCT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 21 analysts
BUY
Median target
$101.00
+59.2%
6 28.6%
Strong Buy
11 52.4%
Buy
3 14.3%
Hold
1 4.8%
Sell
0 0.0%
Strong Sell
12-Month Price Target
14 analysts · 2026-10-01Mean target $101.79 +60.4%
← Below all targets
Current price $63.46
Low$70.00
Mean$101.79
High$137.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Jul 30, 2026